financetom
Business
financetom
/
Business
/
Eaton Boosts 2024 Guidance As Electrical And Aerospace Sectors Excel
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Eaton Boosts 2024 Guidance As Electrical And Aerospace Sectors Excel
Apr 30, 2024 8:10 AM

Eaton Corporation plc ( ETN ) on Tuesday reported a first-quarter FY24 net sales growth of 8% Y/Y to $5.94 billion, beating the consensus of $5.91 billion.

Organic growth of 8% Y/Y was at the high end of guidance in the quarter.

Sales by segments: Electrical Americas $2.7 billion (+17% Y/Y), Electrical Global $1.5 billion (flat Y/Y), Aerospace $871 million (+9% Y/Y), Vehicle $724 million (-2% Y/Y) and eMobility $158 million (+7% Y/Y).

Eaton reported strong growth in the Electrical sector backlog, up 27% with a book-to-bill ratio of 1.2, and the Aerospace backlog, up 11% with a book-to-bill ratio of 1.1.

Total segment operating profit margin expanded by 340 bps Y/Y to 23.1%.

Eaton’s operating cash flow in the quarter was $475 million, up 42% Y/Y, and free cash flow was $292 million (+40% Y/Y).

Adjusted EPS improved 28% Y/Y to $2.40, beating the consensus of $2.29.

Craig Arnold, Eaton chairman and chief executive officer said,  “Growth drivers like increased project activity tied to megatrends, reindustrialization and infrastructure spending continue to drive demand for Eaton’s solutions across our markets, and we remain very confident in our teams’ ability to execute on our increased targets for the year.” 

“We capitalized on strong growth in our business to start the year, resulting in strong order growth in Electrical and Aerospace and first quarter record segment margins.”

Related: Eaton Is Poised To Benefit From ‘Ongoing Electrical Super-Cycle,’ Says Bullish Analyst

Q2 FY24 Outlook: The company expected Adjusted EPS of $2.52-$2.62 versus $2.50 consensus, organic revenue growth of 6.5%-8.5%, and segment operating margins of 22.4%-22.8%.

FY24 Guidance, raised: Eaton increased adjusted EPS to $10.20-$10.60 (from $9.95-$10.35 prior) vs. $10.25 estimate, organic revenue growth to 7%-9% (from 6.5%-8.5%) and segment operating margins to 22.8%-23.2% (from 22.4%-22.8%).

Investors can gain exposure to the stock via First Trust NASDAQ Clean Edge Smart Grid Infrastructure Index Fund and Neuberger Berman ETF Trust Neuberger Berman Carbon Transition Infrastructure ETF .

Price Action: ETN shares are down 1.4% at $321.93 at last check Tuesday.

Now Read: Goldman Sachs Tempers Investor Excitement On Tesla Self-Driving Tech In China: ‘Not Yet An Eyes-Off, Unsupervised Product’

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
US court blocks Kroger's $25 billion acquisition of grocery rival Albertsons
US court blocks Kroger's $25 billion acquisition of grocery rival Albertsons
Dec 10, 2024
(Reuters) - A U.S. judge blocked the pending $25 billion merger of U.S. grocery chains Kroger and Albertsons on Tuesday, siding with the U.S. Federal Trade Commission in a win for the Biden administration. The FTC argued at a three-week trial in Portland, Oregon, that the merger would eliminate head-to-head competition between the top two traditional grocery chains, leading to...
Jazz Pharmaceuticals Likely to Launch FDA-Approved Biliary Tract Cancer Treatment in 2025, RBC Says
Jazz Pharmaceuticals Likely to Launch FDA-Approved Biliary Tract Cancer Treatment in 2025, RBC Says
Dec 10, 2024
03:32 PM EST, 12/10/2024 (MT Newswires) -- Jazz Pharmaceuticals' ( JAZZ ) investor event on Wednesday is expected to set the stage for commercial launch possibly next year of its biliary tract cancer treatment Ziihera, RBC Capital Markets said in a note. The US Food and Drug Administration's accelerated approval of Ziihera brings Jazz a step closer towards new revenue...
Siga's mpox drug did not improve lesion resolution or pain, NIH study finds
Siga's mpox drug did not improve lesion resolution or pain, NIH study finds
Dec 10, 2024
Dec 10 (Reuters) - Siga Technologies' ( SIGA ) antiviral drug tecovirimat did not reduce the time to lesion resolution or have an effect on pain among adults affected by the clade II strain of mpox, according to a National Institutes of Health study published on Tuesday. ...
US court blocks Kroger's $25 billion acquisition of grocery rival Albertsons
US court blocks Kroger's $25 billion acquisition of grocery rival Albertsons
Dec 10, 2024
Dec 10 (Reuters) - A U.S. judge blocked the pending $25 billion merger of U.S. grocery chains Kroger ( KR ) and Albertsons ( ACI ) on Tuesday, siding with the U.S. Federal Trade Commission in a win for the Biden administration. The FTC argued at a three-week trial in Portland, Oregon, that the merger would eliminate head-to-head competition between...
Copyright 2023-2026 - www.financetom.com All Rights Reserved